tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

JSPR Stock Latest News

Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
RatingsBriquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
1d ago
JSPR
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
PremiumCompany Announcements
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
2d ago
8K
JSPR
Jasper Therapeutics reports updated data from briquilimab studies
PremiumThe Fly
Jasper Therapeutics reports updated data from briquilimab studies
2d ago
JSPR
Maintaining Hold on Jasper: Awaiting Critical BEACON CSU Data to Resolve Clinical and Execution Uncertainty
PremiumRatings
Maintaining Hold on Jasper: Awaiting Critical BEACON CSU Data to Resolve Clinical and Execution Uncertainty
2d ago
JSPR
Jasper Therapeutics announces leadership transition and briquilimab update
PremiumCompany Announcements
Jasper Therapeutics announces leadership transition and briquilimab update
2d ago
8K
JSPR
Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO
PremiumThe FlyJasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO
2d ago
JSPR
3 Penny Stocks to Watch Now, 12/4/25
Premium
Market News
3 Penny Stocks to Watch Now, 12/4/25
1M ago
BQ
FTEL
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab’s Promising Data and Strategic Plans
Premium
Ratings
Positive Outlook for Jasper Therapeutics: Buy Rating Reinforced by Briquilimab’s Promising Data and Strategic Plans
1M ago
JSPR
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy Rating
PremiumRatings
Jasper Therapeutics: Strategic Patient Selection and Consistent Drug Performance Justify Buy Rating
1M ago
JSPR
Jasper Therapeutics Reports Positive Phase 1b Study Results
PremiumCompany Announcements
Jasper Therapeutics Reports Positive Phase 1b Study Results
1M ago
8K
JSPR
Jasper Therapeutics reports data from ETESIAN Phase 1b study
PremiumThe Fly
Jasper Therapeutics reports data from ETESIAN Phase 1b study
1M ago
JSPR
Jasper Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Jasper Therapeutics Reports Q3 2025 Financial Results
2M ago
JSPR
Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating
PremiumRatingsPositive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating
2M ago
JSPR
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts
Premium
Ratings
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts
2M ago
JSPR
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)
Premium
The Fly
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)
2M ago
JSPR
Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications
PremiumCompany Announcements
Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications
2M ago
JSPR
Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria
PremiumCompany Announcements
Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria
2M ago
JSPR
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
PremiumThe Fly
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
4M ago
JSPR
Jasper Therapeutics Announces $30 Million Public Offering
PremiumCompany Announcements
Jasper Therapeutics Announces $30 Million Public Offering
4M ago
8K
JSPR
Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43
PremiumThe FlyJasper Therapeutics 11.67M share Spot Secondary priced at $2.43
4M ago
JSPR
Jasper Therapeutics announces common stock offering, no amount given
Premium
The Fly
Jasper Therapeutics announces common stock offering, no amount given
4M ago
JSPR
Jasper Therapeutics price target lowered to $25 from $29 at UBS
Premium
The Fly
Jasper Therapeutics price target lowered to $25 from $29 at UBS
5M ago
JSPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >